Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04707157 · ClinicalTrials.gov registry record · Phase 2
Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT04707157 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 68 participants.
The verdict
NCT04707157, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
This study is being done to test the safety and efficacy of the study drug LY3556050 for the treatment of diabetic peripheral neuropathic pain. This trial is part of the chronic pain master protocol (H0P-MC-CPMP) which is a protocol to accelerate the development of new treatments for chronic pain.
Interventions
- DRUG Placebo
- DRUG LY3556050
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2021-05-06 |
| Est. Completion | 2022-06-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04707157
The ClinicalTrials.gov registry entry for NCT04707157 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04707157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04707157 about?
NCT04707157 is a clinical study titled "Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain". This study is being done to test the safety and efficacy of the study drug LY3556050 for the treatment of diabetic peripheral neuropathic pain. This trial is part of the chronic pain master protocol (H0P-MC-CPMP) which is a protocol to accelerate the development of new treatments for chronic pain.
What is the current status of trial NCT04707157?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2021-05-06. Estimated completion is 2022-06-13.
What interventions are being tested in trial NCT04707157?
The interventions under investigation include: Placebo (DRUG), LY3556050 (DRUG).
Who is sponsoring clinical trial NCT04707157?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.